» Articles » PMID: 29184982

D2A Sequence of the Urokinase Receptor Induces Cell Growth Through αvβ3 Integrin and EGFR

Overview
Publisher Springer
Specialty Biology
Date 2017 Nov 30
PMID 29184982
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The urokinase receptor (uPAR) stimulates cell proliferation by forming a macromolecular complex with αvβ3 integrin and the epidermal growth factor receptor (EGFR, ErbB1 or HER1) that we name the uPAR proliferasome. uPAR transactivates EGFR, which in turn mediates uPAR-initiated mitogenic signal to the cell. EGFR activation and EGFR-dependent cell growth are blocked in the absence of uPAR expression or when uPAR activity is inhibited by antibodies against either uPAR or EGFR. The mitogenic sequence of uPAR corresponds to the D2A motif present in domain 2. NMR analysis revealed that D2A synthetic peptide has a particular three-dimensional structure, which is atypical for short peptides. D2A peptide is as effective as EGF in promoting EGFR phosphorylation and cell proliferation that were inhibited by AG1478, a specific inhibitor of the tyrosine kinase activity of EGFR. Both D2A and EGF failed to induce proliferation of NR6-EGFR-K721A cells expressing a kinase-defective mutant of EGFR. Moreover, D2A peptide and EGF phosphorylate ERK demonstrating the involvement of the MAP kinase signalling pathway. Altogether, this study reveals the importance of sequence D2A of uPAR, and the interdependence of uPAR and EGFR.

Citing Articles

The X-Linked Tumor Suppressor TSPX Regulates Genes Involved in the EGFR Signaling Pathway and Cell Viability to Suppress Lung Adenocarcinoma.

Kido T, Kong H, Lau Y Genes (Basel). 2025; 16(1).

PMID: 39858622 PMC: 11764513. DOI: 10.3390/genes16010075.


Human antibody V domains targeting uPAR as candidate therapeutics for cancers.

Chu X, Li W, Hines M, Lyakhov I, Mellors J, Dimitrov D Front Oncol. 2023; 13:1194972.

PMID: 37876962 PMC: 10593477. DOI: 10.3389/fonc.2023.1194972.


Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.

Alfano D, Franco P, Stoppelli M Front Cell Dev Biol. 2022; 10:818616.

PMID: 35493073 PMC: 9045800. DOI: 10.3389/fcell.2022.818616.


Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer.

Masucci M, Minopoli M, Di Carluccio G, Motti M, Carriero M Cancers (Basel). 2022; 14(3).

PMID: 35158766 PMC: 8833673. DOI: 10.3390/cancers14030498.


uPAR: An Essential Factor for Tumor Development.

Lv T, Zhao Y, Jiang X, Yuan H, Wang H, Cui X J Cancer. 2021; 12(23):7026-7040.

PMID: 34729105 PMC: 8558663. DOI: 10.7150/jca.62281.


References
1.
Huai Q, Zhou A, Lin L, Mazar A, Parry G, Callahan J . Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol. 2008; 15(4):422-3. PMC: 2443823. DOI: 10.1038/nsmb.1404. View

2.
Shapiro R, Duquette J, Roses D, Nunes I, Harris M, Kamino H . Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. 1996; 56(15):3597-604. View

3.
Gordon E, Venkatesan N, Salazar R, Tang H, Buckley S, Warburton D . Factor XII-induced mitogenesis is mediated via a distinct signal transduction pathway that activates a mitogen-activated protein kinase. Proc Natl Acad Sci U S A. 1996; 93(5):2174-9. PMC: 39930. DOI: 10.1073/pnas.93.5.2174. View

4.
Resnati M, Pallavicini I, Daverio R, Sidenius N, Bonini P, Blasi F . Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR). J Immunol Methods. 2006; 308(1-2):192-202. DOI: 10.1016/j.jim.2005.10.013. View

5.
Karamanavi E, Angelopoulou K, Lavrentiadou S, Tsingotjidou A, Abas Z, Taitzoglou I . Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice. Transl Oncol. 2014; 7(2):174-187.e5. PMC: 4101295. DOI: 10.1016/j.tranon.2014.02.002. View